NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Average Recommendation of “Hold” from Analysts

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has been assigned a consensus recommendation of “Hold” from the six brokerages that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $36.75.

A number of analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating on shares of NRx Pharmaceuticals in a research report on Wednesday, January 21st. Ascendiant Capital Markets reiterated a “buy” rating and issued a $48.00 target price (up from $47.00) on shares of NRx Pharmaceuticals in a research note on Friday, January 2nd. Wall Street Zen raised shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, November 23rd. BTIG Research reaffirmed a “buy” rating and issued a $25.00 price target on shares of NRx Pharmaceuticals in a report on Wednesday. Finally, D. Boral Capital restated a “buy” rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday.

NRx Pharmaceuticals Stock Performance

NASDAQ:NRXP opened at $1.84 on Friday. NRx Pharmaceuticals has a 52 week low of $1.58 and a 52 week high of $3.84. The firm has a 50-day moving average price of $2.18 and a two-hundred day moving average price of $2.55. The firm has a market cap of $58.64 million, a price-to-earnings ratio of -0.78 and a beta of 1.91.

Institutional Trading of NRx Pharmaceuticals

A number of institutional investors have recently modified their holdings of NRXP. Anson Funds Management LP boosted its holdings in shares of NRx Pharmaceuticals by 50.3% in the fourth quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock worth $8,249,000 after acquiring an additional 1,018,853 shares during the period. Vanguard Group Inc. boosted its stake in NRx Pharmaceuticals by 18.3% during the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after buying an additional 82,781 shares during the period. Commonwealth Equity Services LLC purchased a new position in NRx Pharmaceuticals during the fourth quarter worth about $994,000. AdvisorShares Investments LLC grew its position in NRx Pharmaceuticals by 29.7% during the third quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock worth $1,129,000 after buying an additional 78,339 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in NRx Pharmaceuticals by 17.8% in the fourth quarter. Geode Capital Management LLC now owns 218,866 shares of the company’s stock valued at $593,000 after acquiring an additional 33,004 shares during the last quarter. 4.27% of the stock is currently owned by hedge funds and other institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.